Abstract Number: 2198 • ACR Convergence 2024
Severe and Long-Term Outcomes of COVID-19 Infection and Vaccine Hesitancy and Adverse Events in Children with Pediatric Rheumatic Diseases: Insights from a COVID-19 Global Rheumatology Alliance Caregiver Survey
Background/Purpose: Children have the lowest COVID-19 vaccination rates of any age group. In adults with rheumatic diseases, barriers to vaccination include the perceived lack of…Abstract Number: PP01 • ACR Convergence 2024
An OCEAN of Change: The Impact of an RA Diagnosis on My Big Five Personality Traits
Background/Purpose: Until age 32, I was a healthy, confident, extraverted, and creative person. I moved hundreds of miles away for college and then earned a…Abstract Number: 0456 • ACR Convergence 2024
Use of Machine Learning to Evaluate Incremental Value of Actigraphy Data for Classifying Treatment Response in Patients with Rheumatoid Arthritis
Background/Purpose: Digital health technology to collect electronic patient reported outcomes (ePRO) and biosensor data are increasingly used to generate real-world data in pharmacoepidemiology. However, the…Abstract Number: 0679 • ACR Convergence 2024
Comparing Raynaud’s Phenomenon Measurement Tools: Results of the Optimizing Raynaud Phenomenon Outcome Measures in Systemic Sclerosis (ROSS) Study
Background/Purpose: Raynaud’s phenomenon (RP) is the most common symptom in systemic sclerosis (SSc) and can lead to significant morbidity, including digital ulcers and/or gangrene. Despite…Abstract Number: 1194 • ACR Convergence 2024
Treatment Effect of Lorecivivint Across Multiple Trials in Patients with Knee OA: A Meta-analysis
Background/Purpose: Lorecivivint (LOR), an intra-articular (IA) CLK/DYRK inhibitor thought to modulate inflammatory and Wnt pathways has previously appeared safe, improved patient-reported outcomes (PROs) compared with…Abstract Number: 1285 • ACR Convergence 2024
The Impact of Race and Social Determinants of Health on Patient Reported Outcomes in Pediatric Lupus: A CARRA Registry Study
Background/Purpose: Minoritized race and social determinants of health (SDoH) are associated with lower achievement of the low lupus disease activity state (LLDAS) and higher cumulative…Abstract Number: 1480 • ACR Convergence 2024
Sustained Improvements with Bimekizumab in Spinal Mobility, Physical Function and Health-Related Quality of Life in Patients with Axial Spondyloarthritis: 2-Year Results from Two Phase 3 Studies
Background/Purpose: In the phase 3 BE MOBILE 1 and 2 studies, bimekizumab (BKZ), a monoclonal IgG1 antibody that inhibits interleukin (IL)-17F in addition to IL-17A,…Abstract Number: 2093 • ACR Convergence 2024
Treatment of Advanced Knee OA with Lorecivivint Leads to Improved Long-Term Patient Acceptable Symptom State (PASS) Compared to Placebo: Data from Phase 3 Extension Trial
Background/Purpose: Lorecivivint (LOR), an intra-articular CLK/DYRK inhibitor thought to modulate inflammatory and Wnt pathways, demonstrated beneficial effects on clinical and radiographic outcomes in previous knee…Abstract Number: 2209 • ACR Convergence 2024
Impact of Common Infections on Medication Interruptions, Quality of Life, and Disease Flares in Patients with Rheumatoid Arthritis
Background/Purpose: Serious infections are a major cause of morbidity and mortality in patients with RA, but less is known about more common, non-serious infections. We…Abstract Number: PP03 • ACR Convergence 2024
How Completing a Systematic Literature Review Improved How I Research My Own Rheumatoid Arthritis and Comorbidities
Background/Purpose: Twelve years ago, I was diagnosed with rheumatoid arthritis (RA). Initially, I was hopeful that the first biologic DMARD would slow the disease and…Abstract Number: 0534 • ACR Convergence 2024
Patient Reported Outcomes and Disease Activity from a Phase 1 Double-Blind Randomized Clinical Trial of Allogeneic Mesenchymal Stem Cells in Early Rheumatoid Arthritis
Background/Purpose: Mesenchymal stem (stromal) cells (MSCs) constitute an emerging therapeutic strategy for several human diseases. Small non-randomized studies have shown that MSCs may be a…Abstract Number: 0680 • ACR Convergence 2024
Clinical Correlates of Physical and Mental Health in Early Systemic Sclerosis: Data from the Collaborative National Quality and Efficacy (CONQUER) Registry
Background/Purpose: Early years of Systemic sclerosis (SSc) are typically the period of peak disease activity and associated with greater pain, fatigue, sleep disturbance, physical impairment,…Abstract Number: 1229 • ACR Convergence 2024
Frequency of Fibromyalgia Using Validated Measures in a Sample of Patients with Psoriatic Arthritis and Impact on Disease: A Cross-Sectional Multinational Study
Background/Purpose: Fibromyalgia (FM), a chronic pain disorder, is more prevalent in psoriatic arthritis (PsA) patients, impacting quality of life and potentially leading to unnecessary treatment escalation. Cultural factors may…Abstract Number: 1320 • ACR Convergence 2024
Acceptability and Satisfaction of an Online Resilience-Building Intervention with Peer Health Coaches for Managing Fatigue and Well-Being in Systemic Sclerosis
Background/Purpose: Non-pharmacological fatigue management interventions in systemic sclerosis (SSc) are limited, despite people with SSc reporting that fatigue is inadequately addressed with clinical care. We…Abstract Number: 1500 • ACR Convergence 2024
Work-Related Disability and Function in Systemic Lupus Erythematosus (SLE): Outcomes of an Exploratory Study from Different Canadian Centres
Background/Purpose: Systemic lupus erythematosus (SLE) has a significant and long-lasting impact on work outcomes, is a source of long-lasting work disability, and presents challenges with…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 43
- Next Page »